Metabolic reprogramming in clear cell renal cell carcinoma

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

Research in many cancers has uncovered changes in metabolic pathways that control tumour energetics and biosynthesis, so-called metabolic reprogramming. Studies in clear cell renal cell carcinoma (ccRCC) have been particularly revealing, leading to the concept that ccRCC is a metabolic disease. ccRCC is generally accompanied by reprogramming of glucose and fatty acid metabolism and of the tricarboxylic acid cycle. Metabolism of tryptophan, arginine and glutamine is also reprogrammed in many ccRCCs, and these changes provide opportunities for new therapeutic strategies, biomarkers and imaging modalities. In particular, metabolic reprogramming facilitates the identification of novel and repurposed drugs that could potentially be used to treat ccRCC, which when metastatic has currently limited long-term treatment options. Further research and dissemination of these concepts to nephrologists and oncologists will lead to clinical trials of therapeutics specifically targeted to tumour metabolism, rather than generally toxic to all proliferating cells. Such novel agents are highly likely to be more effective and to have far fewer adverse effects than existing drugs.

Original languageEnglish (US)
Pages (from-to)410-419
Number of pages10
JournalNature Reviews Nephrology
Volume13
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Renal Cell Carcinoma
Drug Repositioning
Neoplasms
Citric Acid Cycle
Poisons
Metabolic Diseases
Metabolic Networks and Pathways
Glutamine
Research
Tryptophan
Arginine
Fatty Acids
Therapeutics
Biomarkers
Clinical Trials
Glucose
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Nephrology

Cite this

Metabolic reprogramming in clear cell renal cell carcinoma. / Wettersten, Hiromi I.; Abuaboud, Omran; Lara, Primo N; Weiss, Robert H.

In: Nature Reviews Nephrology, Vol. 13, No. 7, 01.07.2017, p. 410-419.

Research output: Contribution to journalReview article

@article{f42b16f2b2cd477ea4e9109571334ab0,
title = "Metabolic reprogramming in clear cell renal cell carcinoma",
abstract = "Research in many cancers has uncovered changes in metabolic pathways that control tumour energetics and biosynthesis, so-called metabolic reprogramming. Studies in clear cell renal cell carcinoma (ccRCC) have been particularly revealing, leading to the concept that ccRCC is a metabolic disease. ccRCC is generally accompanied by reprogramming of glucose and fatty acid metabolism and of the tricarboxylic acid cycle. Metabolism of tryptophan, arginine and glutamine is also reprogrammed in many ccRCCs, and these changes provide opportunities for new therapeutic strategies, biomarkers and imaging modalities. In particular, metabolic reprogramming facilitates the identification of novel and repurposed drugs that could potentially be used to treat ccRCC, which when metastatic has currently limited long-term treatment options. Further research and dissemination of these concepts to nephrologists and oncologists will lead to clinical trials of therapeutics specifically targeted to tumour metabolism, rather than generally toxic to all proliferating cells. Such novel agents are highly likely to be more effective and to have far fewer adverse effects than existing drugs.",
author = "Wettersten, {Hiromi I.} and Omran Abuaboud and Lara, {Primo N} and Weiss, {Robert H}",
year = "2017",
month = "7",
day = "1",
doi = "10.1038/nrneph.2017.59",
language = "English (US)",
volume = "13",
pages = "410--419",
journal = "Nature Reviews Nephrology",
issn = "1759-507X",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Metabolic reprogramming in clear cell renal cell carcinoma

AU - Wettersten, Hiromi I.

AU - Abuaboud, Omran

AU - Lara, Primo N

AU - Weiss, Robert H

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Research in many cancers has uncovered changes in metabolic pathways that control tumour energetics and biosynthesis, so-called metabolic reprogramming. Studies in clear cell renal cell carcinoma (ccRCC) have been particularly revealing, leading to the concept that ccRCC is a metabolic disease. ccRCC is generally accompanied by reprogramming of glucose and fatty acid metabolism and of the tricarboxylic acid cycle. Metabolism of tryptophan, arginine and glutamine is also reprogrammed in many ccRCCs, and these changes provide opportunities for new therapeutic strategies, biomarkers and imaging modalities. In particular, metabolic reprogramming facilitates the identification of novel and repurposed drugs that could potentially be used to treat ccRCC, which when metastatic has currently limited long-term treatment options. Further research and dissemination of these concepts to nephrologists and oncologists will lead to clinical trials of therapeutics specifically targeted to tumour metabolism, rather than generally toxic to all proliferating cells. Such novel agents are highly likely to be more effective and to have far fewer adverse effects than existing drugs.

AB - Research in many cancers has uncovered changes in metabolic pathways that control tumour energetics and biosynthesis, so-called metabolic reprogramming. Studies in clear cell renal cell carcinoma (ccRCC) have been particularly revealing, leading to the concept that ccRCC is a metabolic disease. ccRCC is generally accompanied by reprogramming of glucose and fatty acid metabolism and of the tricarboxylic acid cycle. Metabolism of tryptophan, arginine and glutamine is also reprogrammed in many ccRCCs, and these changes provide opportunities for new therapeutic strategies, biomarkers and imaging modalities. In particular, metabolic reprogramming facilitates the identification of novel and repurposed drugs that could potentially be used to treat ccRCC, which when metastatic has currently limited long-term treatment options. Further research and dissemination of these concepts to nephrologists and oncologists will lead to clinical trials of therapeutics specifically targeted to tumour metabolism, rather than generally toxic to all proliferating cells. Such novel agents are highly likely to be more effective and to have far fewer adverse effects than existing drugs.

UR - http://www.scopus.com/inward/record.url?scp=85019246775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019246775&partnerID=8YFLogxK

U2 - 10.1038/nrneph.2017.59

DO - 10.1038/nrneph.2017.59

M3 - Review article

VL - 13

SP - 410

EP - 419

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

SN - 1759-507X

IS - 7

ER -